Galapagos to build fibrosis pipeline via extended Fibrocor partnership

In a move that could refill its fibrosis pipeline, Galapagos expanded its year-old collaboration with Fibrocor, adding options to exclusively license four fibrosis programs.

Under the original deal, announced December 2018, Toronto-based Fibrocor Therapeutics L.P granted Galapagos N.V. (Euronext:GLPG; NASDAQ:GLPG) rights to a small molecule that was in lead optimization against a novel, undisclosed target for idiopathic pulmonary fibrosis (IPF) and other fibrotic indications. ...